Evidence map›Paper›PMID 41399025›Full record

ArticleGut microbes2025

Recipients' native bacteria determine the outcome of FMT treatment in inflammatory bowel disease.

Di Zhao, Xinjun Wang, Ke Wang, Bo Yang, Huiyuan Zhu, Yue Xu, Chen Ye, Long Li, Xiaoqiong Lv, Shailan Zhou and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Di ZhaoDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Xinjun WangDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Ke WangQingdao, China.
Bo YangDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Huiyuan ZhuShanghai Institution of Gut Microbiota Research and Engineering Development, Tenth People's Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Yue XuDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Chen YeDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Long LiDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Xiaoqiong LvDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Shailan ZhouDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Chunlian MaDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Xia ChenDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Fang YinShanghai Institution of Gut Microbiota Research and Engineering Development, Tenth People's Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Yefei ZhuResearch Institute of Intestinal Diseases, Tongji University School of Medicine, Shanghai, China.
Zhan CaoShanghai Institution of Gut Microbiota Research and Engineering Development, Tenth People's Hospital of Tongji University, Tongji University School of Medicine, Shanghai, China.
Ning LiDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.
Tao ZuoGuangdong Institute of Gastroenterology, the Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0001-8450-5281
Huanlong QinSuzhou Key Laboratory of Gut Microecology, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Qiyi ChenDepartment of Colorectal Disease, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University, Shanghai, China.ORCID 0000-0003-4960-3868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFecal microbiota transplantation (FMT) is a promising treatment for inflammatory bowel disease (IBD), achieving clinical response rate of ~50% for ulcerative colitis (UC), and Crohn's disease (CD). While prior research has emphasized donor selection and treatment protocols, the role of the patient's native intestinal microbiota in FMT outcomes remains underexplored.

methodsThis study analyzed a retrospective cohort of 96 IBD patients (45 CD, 51 UC) undergoing FMT, with 192 paired stool samples collected pre- and post-treatment, alongside 332 healthy donor samples from 18 donors. A prospective cohort of 45 IBD patients provided 45 baseline stool samples, and a validation cohort of 112 non-IBD patients contributed 224 paired samples. Retrospective cohort patients were monitored for 4 weeks to assess FMT responsiveness and 52 weeks for treatment effectiveness. Microbiome analysis identified enterotype-specific bacteria and native bacterial genera influence FMT outcomes. Random forest, permissivity, and mathematical models predicted treatment response, characterized microbiome remodeling, and defined microecological remission thresholds.

resultsThe FMT regimen was safe, with no serious adverse events reported. At week 4, the clinical response rates were 58.8% (26/45) for CD patients and 66.7% (34/51) for UC patients; by week 52, the remission rates were 82.4% (37/45) for CD patients and 84.4% (43/51) for UC patients. Microbiome analysis identified 54 bacterial genera linked to enterotype classification, 57 to UC response, and 93 to CD response. Notably, 38 high-frequency retentions of recipient native bacteria after FMT were predictive of FMT responsiveness. The permissivity model revealed a shift toward

conclusionThe patient's native microbiota significantly influences FMT efficacy in IBD, influencing microbiome remodeling and clinical outcomes, highlighting the importance of baseline microbial profiles in predicting FMT responsiveness and optimizing therapy.

Indexed as

BacteriaColitis, UlcerativeCrohn DiseaseFecal Microbiota TransplantationGastrointestinal MicrobiomeInflammatory Bowel DiseasesAdultAgedFecesFemaleHumansMaleMiddle AgedProspective StudiesRetrospective StudiesTreatment Outcomeclinical researchFecal microbiota transplantationinflammatory bowel diseasenative microbiota

Identifiers

PMID41399025
PMCPMC12710938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.